The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / P•••••••••

I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmology

Add-on acquisitionannouncedadd-onannounced Dec 18, 2025Fact
What happened
Platform
I•••add-on basis: I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmology | I••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page
Control
Control
Share acquired
unknown
Industry
healthcare / pharma
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • I•••Platformconfirmed
    I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmology | I••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page
  • I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmology | I••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page
Side not stated
  • M••••• B••••, CEO at I•••, said: “P••••••••• and its team bring deep technical knowledge in ophthalmic HPAPIs and a strong operational base to I•••.
  • I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmology
Evidence
I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmology
I••• acquires P•••••••••, a Highly Potent API manufacturing site specializing in ophthalmo | Private Equity Intelligence | DFX